Spring Mountain Capital, LP Leads Investment in IsoPlexis Corporation

August 5, 2014: Spring Mountain Capital, LP, a New York-based investment management firm, announced today that its private equity group structured and led a growth equity investment in IsoPlexis Corporation.

IsoPlexis has developed a break-through single cell immunoassay and related software that provides in-depth understanding of immune and cancer cells. The Company’s advanced cell assay can identify and characterize up to 45 secreted proteins from individual cells and their effects on the immune system – an amount of information that researchers thus far have been unable to obtain on a single cell basis using currently available methodologies and tools.

Read the rest of this release at Spring Mountain Capital.